Sarah Brenner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah Brenner has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Yonit Wohl
From the Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
8 shared publicationsJacob Mashiah
Department of Dermatology, Tel Aviv Sourasky Medical Center, 6 Weizman St, 64239 Tel Aviv, Israel
5 shared publicationsGoldberg Ilan
From the Department of Dermatology, Tel Aviv‐Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
4 shared publicationsAndrea Gat
From the Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
3 shared publicationsEinat Tamir
Department of Dermatology, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3 shared publicationsHelena Martinez de Morentin
Department of Dermatology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3 shared publications
Latest Publications
- 17 November 2009
- Published by Wiley in International Journal of Dermatology
- Vol. 48 (12) , 1370-1375
Interferon‐γ (INF‐γ) release test can detect cutaneous adverse effects to statins
Background An increasing number of cutaneous adverse effects are being reported as use of statins becomes more widespread. A study was undertaken to establish the relationship between statin and a cutaneous reaction by the in vitro interferon‐γ (INF‐γ) release test.Methods The lymphocytes of 20 patients with suspected drug‐induced skin reaction were incubated with and without the drug. The level of INF‐γ from the supernatant was measured by enzyme‐linked immunosorbent assay (ELISA), and the increase calculated.Results Response was positive in 27 (21.43%) of the 126 drugs. Statin was the only drug with a positive response in 80% of those cases. Nine of 20 patients (45.0%) had complete resolution after discontinuation of the drug; 6 (30.0%) who replaced one drug by another statin had partial or no resolution; and 5 (20.0%) had no resolution despite cessation of statins of all kinds.Conclusion A positive INF‐γ release test was found in patients who developed skin reactions while taking statins; the test’s reliability was strengthened by prompt improvement following elimination of the suspected drug in the majority of patients.
- 17 November 2009
- Published by Wiley in International Journal of Dermatology
- Vol. 48 (12) , 1370-1375
Interferon‐γ (INF‐γ) release test can detect cutaneous adverse effects to statins
Background An increasing number of cutaneous adverse effects are being reported as use of statins becomes more widespread. A study was undertaken to establish the relationship between statin and a cutaneous reaction by the in vitro interferon‐γ (INF‐γ) release test.Methods The lymphocytes of 20 patients with suspected drug‐induced skin reaction were incubated with and without the drug. The level of INF‐γ from the supernatant was measured by enzyme‐linked immunosorbent assay (ELISA), and the increase calculated.Results Response was positive in 27 (21.43%) of the 126 drugs. Statin was the only drug with a positive response in 80% of those cases. Nine of 20 patients (45.0%) had complete resolution after discontinuation of the drug; 6 (30.0%) who replaced one drug by another statin had partial or no resolution; and 5 (20.0%) had no resolution despite cessation of statins of all kinds.Conclusion A positive INF‐γ release test was found in patients who developed skin reactions while taking statins; the test’s reliability was strengthened by prompt improvement following elimination of the suspected drug in the majority of patients.
- Open Access
- 17 December 2007
- Published by Wiley in International Journal of Dermatology
- Vol. 47 (1) , 61-63
A mixed immunoblistering disorder exhibiting features of bullous pemphigoid and pemphigus foliaceus associated with Spirulina algae intake
An 82‐year‐old healthy woman presented with bullae, partly hemorrhagic, on the trunk and extremities (Fig. 1), secreting erosions, and submammary macerations (Fig. 2). The blistering disease developed over a 2‐year period, during which she reported taking no drugs. She did, however, begin using a food supplement containing the blue–green alga Spirulina platensis 1 year before the onset of the eruption. Hemorrhagic bullae on the extremities image Submammary bullae, secreting erosions, and macerations image At admission, the Nikolsky sign was positive. The first biopsy showed a subepidermal bulla with a denuded surface and sparse perivascular lymphocytic infiltrate with scattered eosinophils (Fig. 3). The second biopsy, taken during admission, demonstrated an intra‐ and subcorneal vesicular dermatitis with slight superficial acantholysis. Direct immunofluorescence disclosed immunoglobulin G (IgG) and C3 at the dermoepidermal junction. Indirect immunofluorescence was also positive at the dermoepidermal junction. A salt split test demonstrated IgG, IgM, and C3 on the upper side of the bulla. Immunoblotting of the serum was negative and showed no pemphigoid or pemphigus antigens. Enzyme‐linked immunosorbent assay (ELISA) for desmoglein 1 and 3 antibodies was also negative. The first biopsy showing subepidermal hemorrhagic bulla with denuded surface and sparse perivascular lymphocytic infiltrate with scattered eosinophils (hematoxylin and eosin, ×10) image Diagnostic investigations for neoplasia, Wood's lamp exposure of urine, purified protein derivative (PPD), and antinuclear antibody (ANA) were negative. With a diagnosis of mixed immunoblistering disorder exhibiting features of bullous pemphigoid and pemphigus foliaceus, prednisone 60 mg was started and gradually tapered, and topical treatment was begun with creams containing silver sulfadiazine and triamcinolone/neomycin. Suspecting the involvement of Spirulina in the disease, the food supplement was stopped. With this treatment, the patient steadily improved with no appearance of new blisters. An in vitro interferon‐γ release test with the Spirulina‐containing food supplement, conducted to explore the connection between the agent and the eruption, yielded a slight increase in interferon (19%). The result was considered to be borderline, but, in view of the clinical picture and the fact that the patient was being treated with 20 mg prednisone at the time, the test can be considered as positive. Three months after completion of the prednisone treatment, and with avoidance of the Spirulina‐containing supplement, the patient was free of lesions with no recurrences.
- 17 December 2007
- Published by Wiley in International Journal of Dermatology
- Vol. 47 (1) , 61-63
Open AccessA mixed immunoblistering disorder exhibiting features of bullous pemphigoid and pemphigus foliaceus associated with Spirulina algae intake
An 82‐year‐old healthy woman presented with bullae, partly hemorrhagic, on the trunk and extremities (Fig. 1), secreting erosions, and submammary macerations (Fig. 2). The blistering disease developed over a 2‐year period, during which she reported taking no drugs. She did, however, begin using a food supplement containing the blue–green alga Spirulina platensis 1 year before the onset of the eruption. Hemorrhagic bullae on the extremities image Submammary bullae, secreting erosions, and macerations image At admission, the Nikolsky sign was positive. The first biopsy showed a subepidermal bulla with a denuded surface and sparse perivascular lymphocytic infiltrate with scattered eosinophils (Fig. 3). The second biopsy, taken during admission, demonstrated an intra‐ and subcorneal vesicular dermatitis with slight superficial acantholysis. Direct immunofluorescence disclosed immunoglobulin G (IgG) and C3 at the dermoepidermal junction. Indirect immunofluorescence was also positive at the dermoepidermal junction. A salt split test demonstrated IgG, IgM, and C3 on the upper side of the bulla. Immunoblotting of the serum was negative and showed no pemphigoid or pemphigus antigens. Enzyme‐linked immunosorbent assay (ELISA) for desmoglein 1 and 3 antibodies was also negative. The first biopsy showing subepidermal hemorrhagic bulla with denuded surface and sparse perivascular lymphocytic infiltrate with scattered eosinophils (hematoxylin and eosin, ×10) image Diagnostic investigations for neoplasia, Wood's lamp exposure of urine, purified protein derivative (PPD), and antinuclear antibody (ANA) were negative. With a diagnosis of mixed immunoblistering disorder exhibiting features of bullous pemphigoid and pemphigus foliaceus, prednisone 60 mg was started and gradually tapered, and topical treatment was begun with creams containing silver sulfadiazine and triamcinolone/neomycin. Suspecting the involvement of Spirulina in the disease, the food supplement was stopped. With this treatment, the patient steadily improved with no appearance of new blisters. An in vitro interferon‐γ release test with the Spirulina‐containing food supplement, conducted to explore the connection between the agent and the eruption, yielded a slight increase in interferon (19%). The result was considered to be borderline, but, in view of the clinical picture and the fact that the patient was being treated with 20 mg prednisone at the time, the test can be considered as positive. Three months after completion of the prednisone treatment, and with avoidance of the Spirulina‐containing supplement, the patient was free of lesions with no recurrences.
- Open Access
- 1 August 2007
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 143 (8) , 1001-1004
Immunohistochemical Expression of Platelet Growth Factor and Vascular Endothelial Growth Factor in Patients With Melanoma With and Without Redness (Brenner Sign)
The rise in incidence of malignant melanoma is among the greatest for all kinds of cancer, with an annual rise of 3% to 8% in newly diagnosed melanomas worldwide.1 The increase is especially great in regions of the world where intense sun, especially in the Middle East, and a trend toward more revealing clothing expose people to untoward amounts of UV radiation. Despite efforts to achieve early detection and recognition of the unfavorable prognostic factors and the development of novel treatment modes, progressive disease has a dismal prognosis. Tumor progression and development cannot be attributed to a single process. The escape of the tumor from the regulatory mechanisms includes excessive production of cytokines and autocrine growth factors, substituting for cytokines and exogenous growth factors,2 self-tolerance to melanoma antigens, and down-regulation of class II major histocompatibility complex molecules.3 Neoplasms including melanoma are known to induce angiogenesis, which is believed to have a role in the development and spread of the melanoma.4,5
- 1 August 2007
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 143 (8) , 1001-1004
Open AccessImmunohistochemical Expression of Platelet Growth Factor and Vascular Endothelial Growth Factor in Patients With Melanoma With and Without Redness (Brenner Sign)
The rise in incidence of malignant melanoma is among the greatest for all kinds of cancer, with an annual rise of 3% to 8% in newly diagnosed melanomas worldwide.1 The increase is especially great in regions of the world where intense sun, especially in the Middle East, and a trend toward more revealing clothing expose people to untoward amounts of UV radiation. Despite efforts to achieve early detection and recognition of the unfavorable prognostic factors and the development of novel treatment modes, progressive disease has a dismal prognosis. Tumor progression and development cannot be attributed to a single process. The escape of the tumor from the regulatory mechanisms includes excessive production of cytokines and autocrine growth factors, substituting for cytokines and exogenous growth factors,2 self-tolerance to melanoma antigens, and down-regulation of class II major histocompatibility complex molecules.3 Neoplasms including melanoma are known to induce angiogenesis, which is believed to have a role in the development and spread of the melanoma.4,5
- 2 July 2007
- Published by Wiley in SKINmed: Dermatology for the Clinician
- Vol. 6 (4) , 163-165
A Survey of Sex Differences in 249 Pemphigus Patients and Possible Explanations
Background. Pemphigus, an immunoblistering disorder, is reported with equal or near equal frequencies in men and women despite prominent female predominance in prevalence ratios of the vast majority of autoimmune diseases. Objective. To assess a possible correlation between pemphigus and intake of sex hormones in a cohort of pemphigus patients. Methods. A prospective online survey using a specially designed questionnaire was conducted among patients with diagnosed pemphigus in the United States during a 1‐year period from September 2005 through September 2006. Results. A total of 249 pemphigus cases were enrolled, 158 women (63%) and 91 men (36%). The female‐to‐male ratio was 1.7:1. Age at onset of the disease ranged from 16 to 85 years, mean 4.4±12.9 years for both sexes (not statistically significant): 45.3 for women and 45.7 for men. At the time of pemphigus diagnosis, 12% (20 of 158) of the women and 4% (4 of 91) of the men reported using hormone replacement therapy. At the time of disease onset, 46% (20 of 43) of the postmenopausal women took hormone replacement therapy. Limitations. Possible questionnaire self‐reporting biases. Conclusions. The finding of a female predominance among pemphigus patients is attributed to the immunopathogenesis of the disease that makes women more susceptible to this and other autoimmune disorders and to the strikingly high proportion of hormone replacement therapy users found among postmenopausal women.
- 2 July 2007
- Published by Wiley in SKINmed: Dermatology for the Clinician
- Vol. 6 (4) , 163-165
A Survey of Sex Differences in 249 Pemphigus Patients and Possible Explanations
Background. Pemphigus, an immunoblistering disorder, is reported with equal or near equal frequencies in men and women despite prominent female predominance in prevalence ratios of the vast majority of autoimmune diseases. Objective. To assess a possible correlation between pemphigus and intake of sex hormones in a cohort of pemphigus patients. Methods. A prospective online survey using a specially designed questionnaire was conducted among patients with diagnosed pemphigus in the United States during a 1‐year period from September 2005 through September 2006. Results. A total of 249 pemphigus cases were enrolled, 158 women (63%) and 91 men (36%). The female‐to‐male ratio was 1.7:1. Age at onset of the disease ranged from 16 to 85 years, mean 4.4±12.9 years for both sexes (not statistically significant): 45.3 for women and 45.7 for men. At the time of pemphigus diagnosis, 12% (20 of 158) of the women and 4% (4 of 91) of the men reported using hormone replacement therapy. At the time of disease onset, 46% (20 of 43) of the postmenopausal women took hormone replacement therapy. Limitations. Possible questionnaire self‐reporting biases. Conclusions. The finding of a female predominance among pemphigus patients is attributed to the immunopathogenesis of the disease that makes women more susceptible to this and other autoimmune disorders and to the strikingly high proportion of hormone replacement therapy users found among postmenopausal women.
- 5 March 2007
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 21 (4) , 548-549
Acetaminophen‐induced lichenoid keratosis: a new way to look at an old lesion
- 5 March 2007
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 21 (4) , 548-549
Acetaminophen‐induced lichenoid keratosis: a new way to look at an old lesion
- Open Access
- 1 March 2007
- Published by SAGE Publications in Women's Health
- Vol. 3 (2) , 127-129
Gender as a Roadmap to Dermatological Diseases
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.
- 1 March 2007
- Published by SAGE Publications in Women's Health
- Vol. 3 (2) , 127-129
Open AccessGender as a Roadmap to Dermatological Diseases
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.
- 1 September 2006
- Published by Wiley in SKINmed: Dermatology for the Clinician
- Vol. 5 (5) , 233-237
A Possible Additional Diagnostic Tool for Cutaneous Melanoma
- 1 September 2006
- Published by Wiley in SKINmed: Dermatology for the Clinician
- Vol. 5 (5) , 233-237
A Possible Additional Diagnostic Tool for Cutaneous Melanoma
- 31 August 2006
- Published by Elsevier in Clinics in Dermatology
- Vol. 24 (4) , 334-335
The First World Congress on Gender-Specific Medicine, Berlin, Germany, February 23–26, 2006
- 31 August 2006
- Published by Elsevier in Clinics in Dermatology
- Vol. 24 (4) , 334-335
The First World Congress on Gender-Specific Medicine, Berlin, Germany, February 23–26, 2006
- 1 July 2006
- Published by Wiley in SKINmed: Dermatology for the Clinician
- Vol. 5 (4) , 164-166
Gender Dermatology—A Revolution in Medical Practice
- 1 July 2006
- Published by Wiley in SKINmed: Dermatology for the Clinician
- Vol. 5 (4) , 164-166
Gender Dermatology—A Revolution in Medical Practice
- 1 July 2006
- Published by Wiley in SKINmed: Dermatology for the Clinician
- Vol. 5 (4) , 186-188
Acute Generalized Exanthematous Pustulosis: A Retrospective Analysis Showing a Clear Predilection for Women
The clinical reaction pattern acute generalized exanthematous pustulosis is increasingly recognized today as drug intake details are more meticulously recorded and diagnostic guidelines are formulated. Nevertheless, the diagnosis and etiology remain unclear. This examination of the clinical and histologic features of acute generalized exanthematous pustulosis, undertaken in a retrospective study of 13 patients in an urban medical center, was aimed at determining the underlying mechanism of the etiology of the disease. Findings include a female predominance and the overwhelming prevalence of acetaminophen as the culprit agent, adding two more components to what is known about acute generalized exanthematous pustulosis. The possible mechanisms of the disease are discussed, enlightened by its appearance in two women in the study who were pregnant when the reaction first erupted.
- 1 July 2006
- Published by Wiley in SKINmed: Dermatology for the Clinician
- Vol. 5 (4) , 186-188
Acute Generalized Exanthematous Pustulosis: A Retrospective Analysis Showing a Clear Predilection for Women
The clinical reaction pattern acute generalized exanthematous pustulosis is increasingly recognized today as drug intake details are more meticulously recorded and diagnostic guidelines are formulated. Nevertheless, the diagnosis and etiology remain unclear. This examination of the clinical and histologic features of acute generalized exanthematous pustulosis, undertaken in a retrospective study of 13 patients in an urban medical center, was aimed at determining the underlying mechanism of the etiology of the disease. Findings include a female predominance and the overwhelming prevalence of acetaminophen as the culprit agent, adding two more components to what is known about acute generalized exanthematous pustulosis. The possible mechanisms of the disease are discussed, enlightened by its appearance in two women in the study who were pregnant when the reaction first erupted.